Citation：
李健.
Copyright ? the editorial department of CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY of West China Medical Publisher. All rights reserved
| 1. | ?Cajal SR. Histologie du système nerveux de l’homme et des vertébrés. Paris: Maloine, 1911: 891-942. |
| 2. | Stout AP. Bizarre smooth muscle tumors of the stomach. Cancer, 1962, 15: 400-409. |
| 3. | Mazur MT, Clark HB. Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol, 1983, 7(6): 507-519. |
| 4. | Edmonson JH, Marks RS, Buckner JC,et al. Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas. Cancer Invest, 2002, 20(5-6): 605-612. |
| 5. | Trent JC, Beach J, Burgess MA,et al. A two-arm phase Ⅱ study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas. Cancer, 2003, 98(12): 2693-2699. |
| 6. | Hirota S, Isozaki K, Moriyama Y,et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science, 1998, 279(5350): 577-580. |
| 7. | Heinrich MC, Corless CL, Duensing A,et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science, 2003, 299(5607): 708-710. |
| 8. | Joensuu H, Roberts PJ, Sarlomo-Rikala M,et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med, 2001, 344(14): 1052-1056. |
| 9. | van Oosterom AT, Judson IR, Verweij J,et al. Update of phase Ⅰ study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer, 2002, 38 Suppl 5: S83-S87. |
| 10. | Demetri GD, von Mehren M, Blanke CD,et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med, 2002, 347(7): 472-480. |
| 11. | Blanke CD, Rankin C, Demetri GD,et al. Phase Ⅲ randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol, 2008, 26(4): 626-632. |
| 12. | Zalcberg JR, Verweij J, Casali PG,et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer, 2005, 41(12): 1751-1757. |
| 13. | Dematteo RP, Ballman KV, Antonescu CR,et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet, 2009, 373(9669): 1097-1104. |
| 14. | Joensuu H, Eriksson M, Sundby Hall K,et al. Onevs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA, 2012, 307(12): 1265-1272. |
| 15. | Zhan WH, China Gastrointestinal Cooperative Group. Efficacy and safety of adjuvant post-surgical therapy with imatinib in patients with high risk of relapsing GIST. 2007 ASCO Annual Meeting. J Clin Oncol, 25: 18s (Suppl, abstr10045). |
| 16. | Li J, Gong JF, Wu AW,et al. Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor. Eur J Surg Oncol, 2011, 37(4): 319-324. |
| 17. | Li J, Gong JF, Li J,et al. Efficacy of imatinib dose escalation in Chinese gastrointestinal stromal tumor patients. World J Gastroenterol, 2012, 18(7): 698-703. |
| 18. | Du CY, Zhou Y, Song C,et al. Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China. Eur J Cancer, 2014, 50(10): 1772-1778. |
| 19. | Demetri GD, van Oosterom AT, Garrett CR,et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet, 2006, 368(9544): 1329-1338. |
| 20. | Demetri GD, Reichardt P, Kang YK,et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet, 2013, 381(9863): 295-302. |
| 21. | Janeway KA, Kim SY, Lodish M,et al. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci USA, 2011, 108(1): 314-318. |
| 22. | Nannini M, Astolfi A, Urbini M,et al. Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST). BMC Cancer, 2014, 14: 685. |
| 23. | Agaram NP, Wong GC, Guo T,et al. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer, 2008, 47(10): 853-859. |
| 24. | Shi E, Chmielecki J, Tang CM,et al. FGFR1 and NTRK3 actionable alterations in “Wild-Type” gastrointestinal stromal tumors. J Transl Med, 2016, 14(1): 339. |
| 25. | https://clinicaltrials.gov/Linsitinib in treating patients with gastrointestinal stromal tumors. NCT01560260. |
| 26. | Falchook GS, Trent JC, Heinrich MC,et al. BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance. Oncotarget, 2013, 4(2): 310-315. |
| 27. | Heinrich MC, Corless CL, Blanke CD,et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol, 2006, 24(29): 4764-4774. |
| 28. | Heinrich MC, Maki RG, Corless CL,et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol, 2008, 26(33): 5352-5359. |
| 29. | Heinrich MC, Marino-Enriquez A, Presnell A,et al. Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors. Mol Cancer Ther, 2012, 11(8): 1770-1780. |
| 30. | Ríos-Moreno MJ, Jaramillo S, Díaz-Delgado M,et al. Differential activation of MAPK and PI3K/AKT/mTOR pathways and IGF1R expression in gastrointestinal stromal tumors. Anticancer Res, 2011, 31(9): 3019-3025. |
| 31. | Bauer S, Duensing A, Demetri GD,et al. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway. Oncogene, 2007, 26(54): 7560-7568. |
| 32. | Sápi Z, Füle T, Hajdu M,et al. The activated targets of mTOR signaling pathway are characteristic for PDGFRA mutant and wild-type rather than KIT mutant GISTs. Diagn Mol Pathol, 2011, 20(1): 22-33. |
| 33. | Ricci R, Maggiano N, Castri F,et al. Role of PTEN in gastrointestinal stromal tumor progression. Arch Pathol Lab Med, 2004, 128(4): 421-425. |
| 34. | Li J, Dang Y, Gao J,et al. PI3K/AKT/mTOR pathway is activated after imatinib secondary resistance in gastrointestinal stromal tumors (GISTs). Med Oncol, 2015, 32(4): 111. |
| 35. | Gleeson FC, Kipp BR, Kerr SE,et al. Kinase genotype analysis of gastric gastrointestinal stromal tumor cytology samples using targeted next-generation sequencing. Clin Gastroenterol Hepatol, 2015, 13(1): 202-206. |
| 36. | Hechtman JF, Zehir A, Mitchell T,et al. Novel oncogene and tumor suppressor mutations in KIT and PDGFRA wild type gastrointestinal stromal tumors revealed by next generation sequencing. Genes Chromosomes Cancer, 2015, 54(3): 177-184. |
| 37. | Gao J, Li J, Li Y,et al. Intratumoral KIT mutational heterogeneity and recurrent KIT/PDGFRA mutations in KIT/PDGFRA wild-type gastrointestinal stromal tumors. Oncotarget, 2016, 7(21): 30241-30249. |
| 38. | Kang G, Bae BN, Sohn BS,et al. Detection of KIT and PDGFRA mutations in the plasma of patients with gastrointestinal stromal tumor. Target Oncol, 2015, 10(4): 597-601. |
| 39. | Wada N, Kurokawa Y, Takahashi T,et al. Detecting secondary c-kit mutations in the peripheral blood of patients with imatinib-resistant gastrointestinal stromal tumor. Oncology, 2016, 90(2): 112-117. |
- 1. ?Cajal SR. Histologie du système nerveux de l’homme et des vertébrés. Paris: Maloine, 1911: 891-942.
- 2. Stout AP. Bizarre smooth muscle tumors of the stomach. Cancer, 1962, 15: 400-409.
- 3. Mazur MT, Clark HB. Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol, 1983, 7(6): 507-519.
- 4. Edmonson JH, Marks RS, Buckner JC,et al. Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas. Cancer Invest, 2002, 20(5-6): 605-612.
- 5. Trent JC, Beach J, Burgess MA,et al. A two-arm phase Ⅱ study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas. Cancer, 2003, 98(12): 2693-2699.
- 6. Hirota S, Isozaki K, Moriyama Y,et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science, 1998, 279(5350): 577-580.
- 7. Heinrich MC, Corless CL, Duensing A,et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science, 2003, 299(5607): 708-710.
- 8. Joensuu H, Roberts PJ, Sarlomo-Rikala M,et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med, 2001, 344(14): 1052-1056.
- 9. van Oosterom AT, Judson IR, Verweij J,et al. Update of phase Ⅰ study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer, 2002, 38 Suppl 5: S83-S87.
- 10. Demetri GD, von Mehren M, Blanke CD,et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med, 2002, 347(7): 472-480.
- 11. Blanke CD, Rankin C, Demetri GD,et al. Phase Ⅲ randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol, 2008, 26(4): 626-632.
- 12. Zalcberg JR, Verweij J, Casali PG,et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer, 2005, 41(12): 1751-1757.
- 13. Dematteo RP, Ballman KV, Antonescu CR,et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet, 2009, 373(9669): 1097-1104.
- 14. Joensuu H, Eriksson M, Sundby Hall K,et al. Onevs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA, 2012, 307(12): 1265-1272.
- 15. Zhan WH, China Gastrointestinal Cooperative Group. Efficacy and safety of adjuvant post-surgical therapy with imatinib in patients with high risk of relapsing GIST. 2007 ASCO Annual Meeting. J Clin Oncol, 25: 18s (Suppl, abstr10045).
- 16. Li J, Gong JF, Wu AW,et al. Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor. Eur J Surg Oncol, 2011, 37(4): 319-324.
- 17. Li J, Gong JF, Li J,et al. Efficacy of imatinib dose escalation in Chinese gastrointestinal stromal tumor patients. World J Gastroenterol, 2012, 18(7): 698-703.
- 18. Du CY, Zhou Y, Song C,et al. Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China. Eur J Cancer, 2014, 50(10): 1772-1778.
- 19. Demetri GD, van Oosterom AT, Garrett CR,et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet, 2006, 368(9544): 1329-1338.
- 20. Demetri GD, Reichardt P, Kang YK,et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet, 2013, 381(9863): 295-302.
- 21. Janeway KA, Kim SY, Lodish M,et al. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci USA, 2011, 108(1): 314-318.
- 22. Nannini M, Astolfi A, Urbini M,et al. Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST). BMC Cancer, 2014, 14: 685.
- 23. Agaram NP, Wong GC, Guo T,et al. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer, 2008, 47(10): 853-859.
- 24. Shi E, Chmielecki J, Tang CM,et al. FGFR1 and NTRK3 actionable alterations in “Wild-Type” gastrointestinal stromal tumors. J Transl Med, 2016, 14(1): 339.
- 25. https://clinicaltrials.gov/Linsitinib in treating patients with gastrointestinal stromal tumors. NCT01560260.
- 26. Falchook GS, Trent JC, Heinrich MC,et al. BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance. Oncotarget, 2013, 4(2): 310-315.
- 27. Heinrich MC, Corless CL, Blanke CD,et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol, 2006, 24(29): 4764-4774.
- 28. Heinrich MC, Maki RG, Corless CL,et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol, 2008, 26(33): 5352-5359.
- 29. Heinrich MC, Marino-Enriquez A, Presnell A,et al. Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors. Mol Cancer Ther, 2012, 11(8): 1770-1780.
- 30. Ríos-Moreno MJ, Jaramillo S, Díaz-Delgado M,et al. Differential activation of MAPK and PI3K/AKT/mTOR pathways and IGF1R expression in gastrointestinal stromal tumors. Anticancer Res, 2011, 31(9): 3019-3025.
- 31. Bauer S, Duensing A, Demetri GD,et al. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway. Oncogene, 2007, 26(54): 7560-7568.
- 32. Sápi Z, Füle T, Hajdu M,et al. The activated targets of mTOR signaling pathway are characteristic for PDGFRA mutant and wild-type rather than KIT mutant GISTs. Diagn Mol Pathol, 2011, 20(1): 22-33.
- 33. Ricci R, Maggiano N, Castri F,et al. Role of PTEN in gastrointestinal stromal tumor progression. Arch Pathol Lab Med, 2004, 128(4): 421-425.
- 34. Li J, Dang Y, Gao J,et al. PI3K/AKT/mTOR pathway is activated after imatinib secondary resistance in gastrointestinal stromal tumors (GISTs). Med Oncol, 2015, 32(4): 111.
- 35. Gleeson FC, Kipp BR, Kerr SE,et al. Kinase genotype analysis of gastric gastrointestinal stromal tumor cytology samples using targeted next-generation sequencing. Clin Gastroenterol Hepatol, 2015, 13(1): 202-206.
- 36. Hechtman JF, Zehir A, Mitchell T,et al. Novel oncogene and tumor suppressor mutations in KIT and PDGFRA wild type gastrointestinal stromal tumors revealed by next generation sequencing. Genes Chromosomes Cancer, 2015, 54(3): 177-184.
- 37. Gao J, Li J, Li Y,et al. Intratumoral KIT mutational heterogeneity and recurrent KIT/PDGFRA mutations in KIT/PDGFRA wild-type gastrointestinal stromal tumors. Oncotarget, 2016, 7(21): 30241-30249.
- 38. Kang G, Bae BN, Sohn BS,et al. Detection of KIT and PDGFRA mutations in the plasma of patients with gastrointestinal stromal tumor. Target Oncol, 2015, 10(4): 597-601.
- 39. Wada N, Kurokawa Y, Takahashi T,et al. Detecting secondary c-kit mutations in the peripheral blood of patients with imatinib-resistant gastrointestinal stromal tumor. Oncology, 2016, 90(2): 112-117.